


ARCHITECT HE4 + CA125 Two strong pillars in the management of ovarian cancer



Put science on your side.




HE4 – A New Biomarker in the Management of Ovarian Cancer



HUMAN EPIDIDYMIS PROTEIN 4 (HE4) has been introduced in the management of Epithelial Ovarian Cancer, and the biomarker complements CA125.

- The combination of both assays raises the sensitivity for detecting Stage I/II disease.1
- HE4 and CA125 together improve the therapy monitoring of patients with Ovarian Cancer.¹
- When used together CA125 and HE4 provide a more accurate preoperative determination of the risk of malignancy in women presenting with pelvic mass.²



EXPRESSION PROFILE OF HE4

- HE4 is a precursor protein to the epididymal secretory protein.³
- HE4 is consistently expressed in ovarian carcinoma with minimal expression in normal ovarian tisue.³
- HE4 is highly up-regulated in early and late stage ovarian cancer, with high sensitivity in early stage disease.³

New Algorithm for the Risk Stratification of Women Presenting Pelvic Mass

ROMA (RISK OF OVARIAN CANCER MALIGNANCY ALGORITHM)²

The combined results of HE4 and CA125 provide the physician a risk stratification index for pre- and postmenopausal women presenting pelvic mass, to distinguish between a low or high risk of finding Epithelial Ovarian Cancer (EOC).

In combination with the outcome of the current standard practices (e.g., pelvic exam, ultra sound, CT scan, biopsy etc.) ROMA provides the physician a useful tool for the optimal treatment for the patient.

ROMA VALUE SPECIFIC TO ABBOTT ARCHITECT⁴ Premenopausal

\geq 7.4% High risk of finding EOC


< 7.4% Low risk of finding EOC

Postmenopausal

 \geq 25.3% High risk of finding EOC

< 25.3% Low risk of finding EOC

ROMA increases the sensitivity and specificity of CA125 alone.



When using the ROMA algorithm the ROC-AUC* raises up to 94.9%

RIGHT PATIENT, RIGHT PHYSICIAN, RIGHT OUTCOME

ARCHITECT HE4 PRODUCT INFORMATION

Method and Systems	Two-step CMIA, ARCHITECT i1000sR/i2000sR/i2000
Time to first result	28 minutes
Throughput i2000sR	Up to 200 tests per hour (i2000/i2000sR)
Limit of Quantitation - LOQ	\leq 20 pmol/L
Calibration Range	0 – 1500 pmol/L; Liquid, ready-to-use, 6-point calibration
Controls	3 levels (50 pmol/L, 175 pmol/L, 700 pmol/L)
Sample Type and Volume	Type: Human serum, including serum separator tubes volume: 150 μL routine and 50 μL for additional test from the same sample cup
Reagent On Board Stability	30 days

ORDERING INFORMATION			
Product	List number	Kit configuration	
Reagents	2P54 -25	100 Test Kit	
Calibrator	2P54 -01	6 x 4.0 ml	
Controls	2P54 -10	3 x 8.0 ml	
i1000 ARCHITECT Software	1P61	1 Disk	
i2000 ARCHITECT Software	3K52	1 Disk	

Abbott ARCHITECT Oncology Assays

part of the comprehensive ARCHITECT menu

AFP CA125 CA15-3 CA19-9 CEA CYFRA 21-1* Free PSA HE4 NSE* ProGRP SCC Total PSA

¹ Moore, R.G. et al., *Gynecol Oncol.* 2007; 108:402-8
² Moore, R.G. et al., *Gynecol. Oncol.* 2009; 112:40-46
³ Drapkin, R. et al., *Cancer Res.* 2005; 6-65

- ⁴ ARCHITECT HE4 Package Insert
- $^{\rm 5}$ Abbott data on file

ARCHITECT, *i*1000SR, *i*2000SR, *i*2000, and *Put science on your side*. are all trademarks of Abbott Laboratories in various jurisdictions

Abbott GmbH & Co. KG Abbott Diagnostics Max-Planck-Ring 2 65205 Wiesbaden, Germany Tel. (+49) 6122 580 Fax (+49) 6122 581244 www.abbottdiagnostics.com For additional laboratory and clinical information visit the website: www.taketherightpath.com



AC2205/uk ARCHITECT HE4 02/10/4